Abstract 456P
Background
Osteogenic augmentation is required in various orthopaedic conditions. Defects caused by removal of malignant or local bone tumours requires reconstructive surgeries to restore skeletal continuity and bone grafts to fill bone defects. Different modalities which can help to increase osteogenesis include autografts, allografts and synthetic bone graft substitutes. Autograft is the gold standard, provides osteogenic, osteoinductive and osteoconductive properties but has limitations of requirement for additional incisions, poor bone quality in elderly patients, increases operation time, causes donor site pain and morbidity and likely permanent residual disability and limited amount. Autograft is the gold standard but is available in limited amount and morbidities associated with it. Bone graft substitutes are costly, limited in quantity and don’t integrate with host bone. Bone allografts are a good option, but not widely used in India and there are sparse reports in literature from developing countries. Our study signifies use of gamma irradiated deep freezed bone allografts in treatment of various bone tumours.
Methods
It’s a prospective descriptive study. Strict inclusion and exclusion criteria, as per standard guidelines of American and European Association of Tissue Banking, were followed. We have a in-house facility of gamma irradiated deep freezed bone allografts available in hospital. 20 patients with giant cell tumours of proximal tibia, proximal ulna and distal radius, aneurysmal bone cysts of proximal humerus and distal radius, etc were operated during one year and followed up for atleast 24 weeks thereafter . Sloof's Criteria was used for assessing osteointegration of grafts.
Results
Allografts have not only accepted well but defects have healed and bone integration is at various stages. Only one patient got infected (5%). 19 out of 20 patients (95 %) in our study group had either attained or at various stages of osteointegration and healing.
Conclusions
We conclude that deep freezed bone allografts is a viable option in patients with large bone defects after resection of bone tumours, thus give satisfactory surgical outcome, with no serious side effects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract